Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. National Taiwan University Hospital / 醫學院附設醫院 (臺大醫院)
  4. Chronic myeloid leukemia in Asia
 
  • Details

Chronic myeloid leukemia in Asia

Journal
International Journal of Hematology
Journal Volume
89
Journal Issue
1
Pages
14-23
Date Issued
2009
Author(s)
Au W.Y.
Caguioa P.B.
Chuah C.
SZU-CHUN HSU  
Jootar S.
Kim D.-W.
Kweon I.-Y.
O'Neil W.M.
Saikia T.K.
Wang J.
DOI
10.1007/s12185-008-0230-0
URI
https://scholars.lib.ntu.edu.tw/handle/123456789/561394
Abstract
Chronic myeloid leukemia (CML) in Asia has an incidence rather lower than in Western countries yet tends to afflict a younger population. As in the West, imatinib mesylate (IM, Glivec) has supplanted busulphan, hydroxyurea and interferon-α as first-line treatment. Its use has resulted in a dramatic decline in the number of hematopoietic stem cell transplantations (HSCT) performed. Although it is expensive, IM induces a complete cytogenetic response in 60-90% of newly diagnosed patients, and up to 10% for those in blastic phase. The standard dose of 400 mg is well tolerated by most patients, although adverse events have been observed, including drug-induced cytopenia. Through the Glivec International Patient Assistance Program, the majority of CML patients has access to IM and can expect prolonged survival, even in the absence of HSCT. However, just as in Western countries, resistance to imatinib has emerged in Asian countries. They will require the novel tyrosine kinase inhibitors (dasatinib, nilotinib) becoming available through either clinical trials or market approval. This review examines the available data on CML in China, Hong Kong, India, the Philippines, Singapore, South Korea, Taiwan and Thailand. ? 2008 The Japanese Society of Hematology.
Subjects
Asia; Chronic myeloid leukemia (CML); Epidemiology; Treatment
SDGs

[SDGs]SDG3

Other Subjects
alpha interferon; alpha1 interferon; alpha1b interferon; alpha2a interferon; alpha2b interferon; bosutinib; busulfan; cytarabine; dasatinib; homoharringtonine; hydroxyurea; imatinib; nilotinib; recombinant granulocyte colony stimulating factor; unclassified drug; Asia; China; chromosome analysis; chronic myeloid leukemia; clinical practice; clinical trial; cytopenia; drug blood level; drug efficacy; drug megadose; drug withdrawal; epidemiological data; event free survival; graft versus host reaction; health care cost; health insurance; hematopoietic stem cell transplantation; Hong Kong; human; incidence; India; long term care; low drug dose; neutropenia; opportunistic infection; optimal drug dose; pancytopenia; Philippines; practice guideline; prognosis; real time polymerase chain reaction; reimbursement; review; risk benefit analysis; risk management; Singapore; South Korea; Taiwan; Thailand; thrombocytopenia; treatment response; unspecified side effect; Asia; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Treatment Outcome
Type
review

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science